 |
| Boehringer Ingelheim is one of the companies profiled in the report |
For over a decade now, Animal Pharm has published an annual 'Top 20 Companies' report containing detailed profiles of leading businesses in the global animal health and nutrition products sector.
During that time, the structure of the industry has altered significantly. Merger and acquisition deals have concentrated shares of the market increasingly in the hands of a few leading players, and have resulted in a clearer split between ownership of interests in the 'medicinal' and 'nutritional' segments of the industry. Over the same period, the expiry of patents on major molecules and new approaches to marketing animal health products have seen OTC sales channels increase in importance and generic manufacturers begin to play a more prominent role.
To reflect the changing nature of the industry, and to provide readers with a broader perspective, this edition of the report has been restructured. Pure animal nutrition businesses have been excluded, sharpening the focus of the study and enabling discussion of more companies that play a significant role in the core animal health market - a definition that spans veterinary pharmaceuticals, biologicals and medicinal feed additives.
Defined along those lines, the global market for animal health products was worth almost US$18.6 billion in 2006. The introductory section of this study discusses the size, structure and recent development of the global market, and examines factors affecting market growth rates. It also includes an analysis of recent merger and acquisition activity in the sector, presents tabulated company sales rankings for 2006 and ranking forecasts for 2007, and assesses the comparative profitability of leading animal health businesses.
More than two-thirds of global market value was generated by 13 major animal health businesses in 2006. Schering-Plough's pending acquisition of Intervet means that by the end of 2007, almost 70% of the market will be concentrated in the hands of 12 companies. SP's expanded animal health business will vie with Pfizer and Merial for outright leadership of the sector, with each of these three giants generating annual sales of more than US$2 billion. The combined market share held by the three leading players will be in excess of one-third.
The first group of profiles contained in the report includes all 12 of these 'animal health majors' - companies that are involved in the development, manufacture and sale of animal health products, and that operate in most of the world's leading national markets. Each profile describes the background and ownership of the relevant business and outlines its contribution to respective corporate sales. Recent performance is outlined through the presentation of five-year tabulated sales data (plus information on earnings where available) and descriptive text. The geography of the business is also analysed, while product portfolios are discussed in detail. An overview of research and development activity is presented, while each profile also includes an analysis of individual business strategies and commercial prospects for individual companies. 
Monsanto generates substantial revenues from a single product, the Posilac bovine somatotropin formulation
The second group of profiles includes 14 businesses that, while not classed as 'animal health majors', play a significant role in the sector. This miscellaneous grouping includes 'second tier' companies such as Janssen and Orion, which boast track records in the discovery and development of proprietary animal health products, and Monsanto, which generates substantial revenues from a single product (its Posilac bovine somatotropin formulation). Leading representatives from the generic and OTC segments of the industry have also been included, along with high-profile players in Asia, some of which act as distributors in key markets that are difficult for multinationals to penetrate directly.
| Animal Pharm's Top Tier Companies Report: 2007 edition (SR263) |
 The report concentrates on the 12 ‘animal health majors’ and a further 14 companies that play a significant role in the sector to give you a broader perspective of the industry.› Find out more › Executive summary › Order the report |
'Double-counting' is also an issue, with Japanese companies in particular generating a substantial proportion of their reported revenues from the sale of multinational brands under licensing agreements with animal health majors. Contract manufacturing muddies the waters further, with some companies reporting revenues generated by toll-based production of products that are subsequently sold by third parties under their own labels, and that, similarly, are included in financial results posted by those companies. Profiles in this section of the report include information on the background of individual businesses, plus an analysis of sales and recent revenue development. The geographical spread of each business is also discussed, product portfolios are analysed, and company strategies and prospects are assessed.
Information sources used to compile this study include the Informa newsletter, Animal Pharm World Animal Health and Nutrition News; a range of other trade press sources; company web sites, annual reports, presentations and other corporate information; personal contacts within the industry; and direct contact with individual companies.
Companies profiled in the report
Animal health "majors": Alpharma, Bayer, Boehringer Ingelheim, Ceva, Elanco, Fort Dodge, Merial, Novartis, Pfizer, Schering-Plough (including Intervet), Vetoquinol, Virbac.
Other significant players
Central Garden & Pet, China Animal Husbandry Industry Co, Dainippon Sumitomo Pharma, Heska, Idexx, Janssen, Kyoritsu Seiyaku, Meiji Seika Kaisha, Monsanto, Nippon Zenyaku Kogyo, Norbrook, Orion, Phibro, Teva.
Email a friend
Digital RSS Feed
